Recursion Pharmaceuticals' stock has plummeted 57% since February, with significant failures in its lead drug REC-994 and other clinical candidates, raising concerns about its AI-driven drug discovery ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...
Recursion ended the year with $603 million in cash and equivalents and expects its cash runway to extend into 2027. This article was generated with the support of AI and reviewed by an editor. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results